FORM 2
THE PATENTS ACT, 1970
(39 of 1970)
&
THE PATENTS RULES, 2003
COMPLETE SPECIFICATION (See section 10, rule 13)
‘ANTI-HISTAMINIC COMPOSITION’
CIPLA LIMITED, 289 BELLASIS ROAD, MUMBAI CENTRAL,
MUMBAI 400008, INDIA.
The following specification particularly describes the invention and the manner in which it is to be performed.

WO 2006/008512 PCT7GB2005/002828

1
ANTI HISTAMINIC COMPOSITION

- The present invention relates to a pharmaceutical composition comprising desloratadine or a pharmaceutically acceptable, salt, solvate, derivative polymorph, hydrate or enantiomer. thereof, to a process for preparing such a composition, and to therapeutic uses thereof.
Desloratadine is DCL or Descarbonylethoxyloratadine or 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5-H-benzo [5,6] cyclohepta [1,2-b] pyridine and possesses antihistaminic properties with substantially no sedative properties.
Desloratadine is an active metabolite of loratadine. It is an oral, long-acting antmistamine that is similar chemically to loratadine. It is 50-fold more potent in-vitro and 10-fold more potent in-vivo than loratadine. It is used to treat the symptoms caused by histamine. Histamine is a chemical that is responsible for many of the signs, and symptoms of allergic reactions, for example, swelling of the lining of the nose, sneezing, and itchy eyes. Histamine is released from histamine-storing cells (mast cells) and then attaches to other cells that have receptors for histamine. The attachment of the histamine to the receptors causes the cell to be "activated", releasing other chemicals, which produce the effects that we associate with allergy.
Desloratadine is a long-acting tricylic histamine agonist with selective H)-receptor histamine antagonist activity. It blocks the H1 receptor for histamine and thus prevents activation of H) receptor-containing cells by histamine. Desloratadine inhibits histamine release from human mast cells in vitro. Desloratadine does not readily enter the brain from the blood and, therefore, causes less drowsiness (sedation). It is a member of a small family of non-sedating antihistamines, which includes loratadine, cetrizine, and azelastine. Use of Desloratadine to relieve hay fever and allergy symptoms, including sneezing; runny nose; and red, itchy, tearing eyes, hives has been reported in the literature.
Desloratadine, a non-sedating antihistamine is disclosed in US Patent No 4,659,716. This US patent also discloses methods of making loratadine, pharmaceutical compositions and methods of using the compositions to treat allergic reactions in mammals.
2
WO2006/008512 PCT/GB2005/002828
2

US Patent No 5,595,997 discloses that desloratadine, a metabolic derivative of loratadine, is used for the treatment of allergic rhinitis, and other disorders, and also avoids the concomitant liability of adverse side-effects associated with other nonsedating antihistamines.
WO0310143 describes pharmaceutical compositions comprising an antihistamine with or without a leukotriene inhibitor for intra nasal delivery to the nasal mucosa.
Methods for treating urinary incontinence comprising administering a therapeutically effective amount of desloratadine, or a pharmaceutically acceptable salt thereof is disclosed in US 5,939,426.
US Patent No 6,100,274 discloses a pharmaceutical composition containing desloratadine (DCL), and a DCL-protective amount of a pharmaceutically acceptable basic salt such as calcium dibasic phosphate, plus an amount of at least one disintegrant, preferably two disintegrants such as microcrystalline cellulose and starch sufficient to provide dissolution of at least about 80% by weight of the pharmaceutical composition in about 45 minutes and suitable for oral administration to treat allergic reactions in mammals such as man are disclosed The use of the basic salt is disclosed as being essential to the stability of the composition. The compositions are said to be substantially free of discoloration and to contain less than 1% by weight of N-Formyl descarbonylethoxyloratadine after storage at 25°C/60% RH for at least 24 months. By contrast, formulations without a basic salt and containing excipients such as mannitol, lactose, and magnesium stearate were all found to be unstable.
Desloratadine is known to be a sensitive molecule that is found to get discoloured and decompose due to harsh temperature and humidity conditions. As taught in US 6,100,274, it is also found to discolor and decompose with incompatible excipients. The discoloration and decomposition at elevated temperature and humidity is accelerated when combined with incompatible (or) highly reactive excipients.
We have recognised that there remains a need for formulations of desloratadine which do not discolor and which are substantially free of desloratadine (DCL) decomposition products, even under accelerated stability conditions.

3

WO 2006/008512 PCT/GB2005/002828

3
An object of the present invention is to provide a formulation of desloratadine which does not discolour and is substantially free from decomposition products- of DCL, especially N-formyl desloratadine, arid is stable even at accelerated conditions.1 The wording "substantially free from decomposition products as used herein, denotes minimal impurities, in particular N-formyl desloratadine.
We have now found that, surprisingly, desloratadine can be satisfactorily stabilised without, in particular, the need to resort to the use of basic salts.
Accordingly, in a first aspect, the present invention provides a stable pharmaceutical composition comprising desloratadine or a pharmaceutically acceptable salt, solvate, derivative, polymorph, hydrate or enantiomer thereof,- and a carrier comprising at least one polyol.
In another aspect, the present invention provides a pharmaceutical composition comprising desloratadine or a pharmaceutically acceptable salt, solvate, derivative, polymorph, hydrate or enantiomer thereof and a carrier comprising at least one polyol, excluding a tablet comprising (mg/tablet) desloratadine (2.5), microcrystalline cellulose (10), mannitol (71.5X pregelinized starch (15) and magnesium stearate (1).
The invention also provides a pharmaceutical composition comprising desloratadine or a pharmaceutically acceptable salt, solvate, derivative, polymorph, hydrate or enantiomer thereof, and a carrier comprising at least one polyol, wherein the composition does not contain one or more of the following ingredients: sugar, such as lactose; stearic acid and derivatives thereof, including sodium stearyl fumerate, magnesium stearate, calcium stearate; aspartame; zinc ascorbate; ascorbyl palmitate.
In another aspect, there is provided a pharmaceutical composition consisting essentially of desloratadine or a pharmaceutically acceptable salt, solvate, derivative, polymorph, hydrate or enantiomer thereof and one or more polyols. Preferably, the composition further consists of one or more of a disintegrating agent, an antioxidant, a chelating agent, and a lubricant.
The compositions of the present invention may optionally be coated. Any suitable coating may be used and coating may, in some instances, improve stability. Film coatings are preferred, but other suitable coatings include wax and sugar coatings (excluding lactose) may be used.
4

WO 2006/00812 PCT/GB2005/002828
4

In another aspect, the invention provides the present compositions for use as medicaments, in particular for -treating conditions responsive to administration of an antihistamine.
According to the present invention there is also provided a stable pharmaceutical composition comprising desloratadine or a pharmaceutically acceptable salt, solvate, derivative, hydrate, polymorph or enantiomer thereof and a stabilizing amount of one or more polyols with one or more pharmaceutically acceptable excipients such that the total impurities amount to less than 1.5 % by weight of the active. Suitably, this means when the composition is stored at 25°C and about 60% relative humidity for a period of at least 24 months. The impurities consist essentially of degradation/decomposition products of the active material.
Desloratadine is a highly reactive compound which when exposed to high temperature and humid storage condition degrades and changes to pink colour. Therefore, extreme caution needs to be taken when formulating desloratadine with various excipients. We have found mat desloratadine is incompatible with common excipients such as lactose and magnesium stearate, microcrystalline stearate and degrades and changes to a pink colour. This decomposition is further accelerated under high temperature and humid conditions.
According to US Patent No 6100274, the main degradant of desloratadine is N-formyl descarbonylethoxyloratadine or N-formyl desloratadine. The formation of the degradation product increases at higher temperature and humidity conditions.
The term "desloratadine" is used herein in a broad sense to include not only desloratadine per se, but also pharmaceutically acceptable salts, solvates, derivatives, polymorphs, hydrates or enantiomers thereof. Polymorphic Forms I and II are preferred forms. These can be used alone or mixtures of Form I and Form II may be used.
By "stable" composition we mean compositions that show compliance to physicochemical parameters, for example which do not show any significant discolouration and which are substantially free of desloratadine (DCL) decomposition products and suitably, the content of drug does not fall below 95% (by weight of the active, and dissolution is not less than 80% by weight of die composition during the specified shelf life. Preferably, this applies even after prolonged (eg 12 or 24 months)
5

WO 2006/008512 PCT/GB2005/002828

5

storage ,at ambient conditions; . Suitably, compositions' of the invention contain total, decomposition products (including N-formyl desloratadine) less than 1.5% by weight of: the: active. Preferably, the amount .of N-formyl impurity is less than 0.7%, preferably less than 0.6%, by weight of the active after storage at\40°C and 75%. relative humidity for at least 1 month, preferably 4 months, more preferably for at least 6 months. Preferably, compositions of the invention contain N-formyl desloratadine less than 0.75%, ideally less man 0.6%, preferably less than 0.5%, by weight of the active after storage at 25°C and 60% relative humidity. Preferably, the period of storage is for at least 12 months, more preferably at least 18 months, and most preferably at least 24 months, at 25°C and 60% relative humidity. We have found that it is possible to provide such stable compositions by using a polyol in combination with the active, without the need to use additional stabilising means such as basic salts.
Accordingly, the invention also provides the use of a polyol to stabilise a pharmaceutical composition comprising desloratadine.
The carrier far the active in the compositions of the invention may comprise one or more polyols alone, but will preferably also include other excipients provided that these do not adversely affect the stability of the active. Compounds which show an acidic pH in water are preferably excluded.
Surprisingly, polyols or sugar alcohols like mannitol, sorbitol, maltitol, xylitol, erythritol and the like (which are used normally as fillers), when used as carriers the degradation and discoloration of the desloratadine is reduced substantially.
Polyol (also known as sugar alcohol, polyhydric alcohol) is a hydrogenated form of carbohydrate, whose carbonyl group (aldehyde or ketone), reducing sugar) has been reduced to a primary or secondary hydroxyl group. They are commonly used as artificial sweeteners. Some of the preferred polyols are mannitol, sorbitol, xylitol, maltitol, lactitiol, erythritol.
Mannitol is preferably D-mannitol. It is a hexahydric alcohol related to mannosc and is isomeric with sorbitol. Mannitol occurs as a white, odourless,
crystalline powder, or free flowing granules.
Sorbitol is preferably D-sorbitol. It occurs as a white or almost white, crystalline powder.
6

WO 2006/008512 PCT/GB2005/002828
6

Xylitol is preferably meso-xylitol. Xylitol occurs as white crystalline powder or
crystals.
Maltitol is preferably D-maltitol. It occurs as a white, crystalline powder.
Lactitol is. preferably D-glucitol. Lactitol is a white crystalline powder.
Erythritol is preferably meso-Erythritol. It occurs as a white or almost white, crystalline powder or free-flowing granules.
The concentration of the said polyol added is suitably from 1-95% by weight of the composition. More preferably, 15-85% by weight of the composition is used. A particularly preferred range is from 50 to 80% by weight, as very good stabilisation is achieved within this range.
The present invention provides a final formulation that is substantially free of impurities, both initially and after prolonged storage. The present invention limits the total impurities to less than 1.5% by weight of the active.
Preferably, the compositions of the invention comprise one or more disintegrating agents. When combined with suitable disintegrants, the formulations show faster disintegration and thereby faster dissolution.
Any suitable disintegrating agent may be used, provided it does not adversely affect the stability of the active. Suitable disintegrating agents include one or more of
starch, modified starch such as partially gelatinised starch, sodium starch glycolate, hydroxypropylcellulose (HPC), low substituted hydroxypropylcellulose (L-HPC) or
croscarmellose sodium. A preferred disintegrant is low substituted
hydroxypropylcellulose. The disintegrating agent is preferably used at in an amount of from 0.5 to 30% by weight of the composition. A range of 5 to 15% by weight is particularly suitable.
The compositions of the invention preferably also contain an antioxidant and/or a chelating agent. The presence of one or more of these compounds can serve to assist in reducing decomposition and/or discoloration of the active. An antioxidant is particularly preferred. The antioxidant and/or chelating agent may be present in an amount of from 0.01% to 1% by weight of the formulation.
A particularly preferred range is from 0.01 to 0.5% by weight of the composition.
7

WO 2006/008512 PCT/GB2005/00282

7
Any suitable antioxidant may be used, but preferred antioxidants include one.or •more of butylated hydroxy anisole, butylated hydroxy toluene, propyl gallate, sodium rnetabisulfite, sodium ascorbate, and vitamin E acetate. Antioxidants at a concentration of about 0.01 to 1% w/w of a tablet more preferably 0.01 toO.5% w/w of a tablet can, for example, be used. The most preferred antioxidant is sodium metabisulphite. The chelating agent may, for example, be disodium edetate.
A preferred composition of the invention is a stable pharmaceutical composition comprising desloratadine or a pharmaceutically acceptable salt, solvate, derivative, hydrate, polymorph or enantiomer thereof, from 50 to 80% polyol, from 5 to 15% disintegrating agent, and from 0.01 to 0.5% of an antioxidant and/or a chelating agent, all by weight of the composition. Preferably an antioxidant is used, and the active is preferably present in an amount of from 2.5 to 5mg (for example, in a tablet, although any suitable dosage form may be used). Preferably, a lubricant is also included.
Other conventional pharmaceutical excipients may be included in the compositions of the invention as required depending upon the nature of the formulation and provided they do not adversely affect the stability of the active.
Other standard pharmaceutical excipients which may be used include one or more of but are not limited to: 1) Fillers like starch etc. 2) Binders: gelatin, pregelatinised starch, hydroxypropyl methylcellulose (HPMC), ethyl cellulose, hydroxy ethylcellulose, hydroxy propylcellulose, etc. 3) Antiadherents, lubricants and glidants like talc, hydrogenated castor oil, hydrogenated vegetable oil, siliconised talc, sucrose esters, silicone or simethicone oil, anhydrous colloidal silica etc, or mixtures of two or more thereof. The antiadherents, lubricants and glidants are preferably used in an amount of from 0.5 to 35% by weight of the composition. Pharmaceutical excipients for solutions or suspensions include sorbitol, propylene glycol, lactitiol, maltitol etc.
The finished product of the present invention can be of any suitable dosage form, for example tablets, capsules, pellets, powders, solutions or suspensions. Preferably the composition is a solid composition, especially a tablet, capsule, or pellet
and the like.
In another preferred embodiment the compositions of the present invention may be coated. The coating may be a film coating, sugar coating (other than lactose) or a
8

WO 2006/008512 PCT/GB2005/002828
8
wax coating, for example, although other suitable coatings, may be used. Film coated tablets are preferred. Preferably the film coat is lactose free. The film coating composition may, for example, be any suitable film coat and may, for example, be film coating redimix or may contain one of. more conventional film forming materials like hydroxypropyl methylcellulose, ethyl cellulose, and hydroxyethylcellulose. Plasticizers, opacifiers, colouring agents, and drying agents etc may also be included. Opacifiers may, for example, be chosen from titanium dioxide, lake of various dyes and iron oxides eg iron oxide red. Colouring agents may, for example, be suitable soluble colour dyes as well as soluble lakes.
Plasticizers may also be included and suitable compounds include one or more of propylene glycol, polyethylene glycol, triethyl citrate, dibutyl sebacate, triacetin, and isopropyl myristate. Suitable vehicles may include for example one or more of water, hydroalcoholic or non-aqueous solvents.
The wax coating may include for example bees wax, gum acacia, carnuba wax, branded grades like opagloss or mixtures thereof using suitable vehicles, for example, isopropyl alcohol, methylene chloride, chloroform or mixtures thereof
m one embodiment the formulation of the present invention may be in the form of a tablet. Tablet formulations of the present invention comprising polyol as an excipient along with other conventional excipients were exposed in a petri dish at 40°C/75% RH for one month. Even after one month, the tablets were found to be free of discolouration and remained white in colour. Upon analysis, the formulations did not show any further rise in degradation level. Stability data for these is given in Table 1.
Tabletting may be done using conventional methods. We prefer to use direct compression. Dry granulation by compaction or slugging may be employed. Nonaqueous granulation with cellulose polymer, such as ethylcellulose, low-substituted hydroxypropylcellulose or hydroxypropylmethyl cellulose as binder, using isopropyl alcohol and methylene dichloride as solvents may also be used. Disodium EDTA may be included.
The compositions of the invention may be coated or uncoated, for example coated or uncoated tablets. For coated compositions, an antioxidant may be included although can be left out if desired.

9
WO 2006/008512 PCT/GB2005/002828

9
The invention therefore provides a stable coated pharmaceutical composition . comprising desloratadine and one or more polyols. Preferably, the composition is a coated tablet.; An antioxidant may optionally be present. The coating is suitably, film;, coated and-preferably lactose free. .It may be a" sugar coating (other than..lactose) eg..; sugar (pharma grade) or a wax coating, for example, although other suitable coatings...
may be used.
The invention also provides a stable uncoated pharmaceutical composition comprising desloratadine, one or more polyols and one or more antioxidants.
In another aspect, the invention provides a process for making a stable pharmaceutical tablet composition comprising desloratadine and one or more polyols, optionally together with other pharmaceutically acceptable excipients, which process comprises blending the ingredients and compressing to form a tablet
The therapeutically effective amount of desloratadine for oral administration may vary, for example, from about 2.5 to 20 mg per day, more preferably from about 5 to 10 mg per day. The most preferred amount is 5mg, once a day.
It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be falling within the scope of the invention.
The following examples are for the purpose of illustration of the invention only and are not intended in any way to limit the scope of the invention.
Example 1:
10
A tablet by direct compression with mannitol (DC grade)


WO 2006/WI8512 PCT/GB2005/002828
10

Manufacturing Procedure:
Desloratadine and mannitol were cosifted to form a drugraix. A blend of the drugmix L
HPC and DC grade mannitol was made and lubricated and compressed to form tablets.

Example 2:
A tablet by wet granulation with mannitol

Manufacturing Procedure:
Desloratadine, mannitol and L HPC were cosifted and granulated with hydroxypropyl cellulose. The wet mass so obtained was dried and passed through mesh. It was further lubricated with talc and compressed to form tablets.

WO 2006/008512 PCT/GB2005/002828
Example3:
A tablet by direct compression with mannitol (DC grade) and antioxidant

Manufacturing Procedure:
Desloratadine, sodium metabisulfite and mannitol were cosifted to form Drug mix. A
blend of Drugmix, L HPC and DC grade mannitol was lubricated and compressed to
form tablets.
Example 4:
12
A tablet by direct compression with mannitol (DC grade) and further coating with a coat composition containing lactose.


WO 2006/008512 PCT/GB2005/002828

Manufacturing Procedure:
Desloratadine and mannitol were cosifted to form Drug mix. A blend of Drug mix, L HPC and DC grade mannitol was lubricated and compressed to form tablets. The tablets were coated with the above coating composition.
Example 5:
13
A tablet by direct compression with Mannitol (DC grade) and coating with a coat composition without lactose.


WO 2006/008512 PCT/GB2005/002828

Manufacturing Procedure:
Desloratadine and mannitol were cosifted to form Drug mix. A blend of Drugmix, L HPC and DC grade mannitol was lubricated and compressed to form tablets. The tablets were coated with the above coating composition.
Example 6:
A tablet by wet granulation using conventional excipients without using any polyol

Manufacturing Procedure:
Desloratadine, starch, crospovidone and microcrystalline cellulose were cosifted to form a blend which was granulated with Starch paste. The wet mass obtained was dried and passed through mesh and lubricated with talc and compressed to form tablets.
14

WO 2006/008512 PCT/GB2005/002828
14
The tablets obtained from Examples 1 to 6 were exposed in an open Petri dish at
25°C/60°/o RH and 40°C/75% RH for 1 month and checked for discoloration, content of desloratadine and the impurity levels. The results are given in Table 1.
Note: for colour and description of coated tablets the tablets exposed for I month were broken and observed.
15

WO 2006/008512 PCT/GB2005/002828
17
Example 7 Capsule form:'

Desloratadine, mannitol and sodium metabisulphite woe cosifted to form a drogmix. The drugmix, L-HPC and DC grade mannitol was blended and lubricated with talc and then encapsulated.
Example 8
18
Tablet by direct compression.


WO 2006/0085:12 PCT/GB2005/002828
b) Compress using suitable tooling Example 11

Desloratadine, DC grade sorbitol were mixed to form a dry mix. A binder solution of L-HPC in isopropyl alcohol and methylene chloride were prepared. The dry mix was granulated using the binder solution. The other excipients and lubricants were added and the resulting blend
was compressed using suitable tooling.
Example 12
20
Tablet by direct compression.


WO 2006/008512 PCT/GB2005/002828
20

Coating

Desloratadine and mannitol were cosifted to form Drug premix. The Drug premix was further blended with L-HPC, silica colloidal anhydrous and DC grade mannitol and this was further lubricated with siliconised talc and castor oil hydrogenated and compressed to form tablets. The tablets were coated with the above coating composition.
Example 13

Coating
21
Tablet by direct compression.


WO 2006/008512 PCT/GB2005/002828

Desloratadine and mannitol were cosifted to form Drug premix. The Drug preraix was further blended with L-HPC, silica colloidal anhydrous and DC grade mannitol and this was further lubricated with siliconised talc and castor oil hydrogenated and compressed to form tablets. . . The tablets were coated with the above coating composition.
The stability of Formulated Tablets of Example 8
Chemical assay, physical properties and degradation of the formulated tablets of Example 8 were studied on samples placed in high density polyethylene bottles and blister packages. No significant changes were observed in the physical appearance, chemical assay of desloratadine and dissolution rate when the tablets of Example 6 were stored in High density polyethylene bottles (HDPE) or blister packages for up to 12 months at 25°C 60 % relative humidity ("RH") or at 30°C / 65% RH or for up to 6 months at-40°C / 75% RH. A small amount of degradation e.g. N-formyl DCL, was observed in the tablets stored in HDPE bottles and in blisters (about 0.5%) at 40°C / 75% RH for 6 months, and only about 0.2 - 0.3 % was observed in samples of the tablets stored in blisters of HDPE bottles for 12 months at 25°C / 60 % or at 30°C / 65% RH.
DC grade as used herein means directly compressible grade.
22


22
CLAIMS:
1. A stable pharmaceutical composition comprising desloratadine or a pharmaceurtically acceptable salt, solvate, derivative, polymorph, hydrate or enantiomer thereof, and a carrier comprising at least one polyol selected from mannitol, maltitol, sorbitol, lactitol, erythritol, or xylitol or a mixture of two or more thereof; -wherein toe composition does not contain stearic acid and derivatives thereof.
2. A composition according to claim 1 wherein the total impurities amount to less than 13% by weight of the active. ',
3. A composition according to claim 1 which contains N-formyl desloratadine less man 0.75% by weight of me active.
4. A composition according to claim 1 which contains N-formyl desloratadine less than. 6% by weight of the active.
t
5. A composition according to claim 1 which contains N-formyl desloratadine less man. 0.5% by weight of the active.
6. A composition according to anyone of claims 2 to 5 wherein the composition has been stored at about 25°C and about 60% relative humidity.
7. A composition according to any one of claims 1 to 6 wherein the amount of polyol is
from 1 to 95% by weight of the composition-

8. A composition according to claim 7 wherein me amount of polyol is from 15 to 85% by weight of the composition.
9. A composition according to claim 8 wherein the amount of polyol is from 50 to 80% by weight of the composition
23

A composition according to any preceding claim further comprising at least one disintegrating agent.
11. A composition according to claim 10 wherein me amount of disintegrating agent is from 0.5 to 30% by weight of me composition.
12. A composition according to claim 10 or 11 wherein the disintegrating agent is starch, modified starch such as partially gelatinised starch, sodium starch glycolate, hydroxypropylcellulose, low substituted hydroxypropylcellulose or croscarmellose sodium or is a mixture of two or more thereof.

13. A composition according to claim 12 wherein the disintegrating agent is low substituted
hydroxypropylcellulose.

14. A composition according to any preceding claim further comprising an antioxidant and/or a chelating agent, of a mixture thereof.
15. A composition according to claim 14 wherein the amount of antioxidant or chelating agent is from 0.01 to 1% by weight of the composition.
16. A composition according to claim 16 wherein fee amount of antioxidant or chelating agent is from 0.01 to 03% by weight of the composition.
17. A composition according to claim 14, 15 or 16 wherein the antioxidant is sodium metabisulfite, butylated hydroxy anisole, butylated hydroxy toluene, propyl gallate, sodium ascorbate, or vitamin E acetate, or is a mixture of two or more thereof
18. A composition according to claim 17 wherein the antioxidant is sodium metabisulfite.

19. A composition according to claim 1comprising in addition to desloratadine, from 50 to
80% polyol, from 5 to 15% disintegrating agent, and from 0.01 to 03% antioxidant and/or chelating agent, all by weight of fee composition.

24


24

20. A composition according to any preceding claim, further comprising a lubricant.

21. A composition: according to claim 20 wherein the lubricant is present in. an amount of from 0.5 to 35% by weight of the composition .
22. A composition according to claim 20 or 21 -wherein the lubricant is talc, hydrogenated castor oil, sillconised talc, anhydrous colloidal silica, sucrose eaten, hydrogenated vegetable oil, silicone or simethicone oil, or is a, mixture of two or more thereof.
23. A composition according to any preceding claim which composition is coated.
24. A composing according to claim 23 wherein the coating is a film-coating a sugar costing ( other than lactose ) or a wax coating.
25. A composition according to claim 23 or 24 which composition is film-coated.
26. A composition according to claim 25 wherein the film coat is free of lactose.
27. A composition according to any preceding claim which composition is free of pharmaceutically acceptable basic salts.
28. A stable pharmaceutical composition, comprising desloratadine or a pharmaceutically
acceptable salt, solvate, derivative, polymorph, hydrate or enantiomer thereof, and a
carrier comprising at least one polyol selected from mannitol, maltitol, sorbitol, lactitol, erythritol, or xylitol or a mixture of two or more thereof; and low-substituted

hydroxypropyl cellulose; wherein the composition does not contain steatric acid and derivatives thereof

29. A Stable pharmaceutical composition comprising desloratadine or a pharmaceutically
acceptable salt, solvate, derivative, polymorph, hydrates or enantiomer thereof and a carrier composing at least one poryol selected from mannitol, maltitol, sorbitol, lactitol, erythritol, or xylitol or a mixture of two or more thereof; and an antioxidant and/or a
25


chelating agent; wherein the composition does not contain stearic acid and derivatives thereof.
30. A composition according to claim 28 or 29 which contains N-formyl desloratadine less than 0.75% by weight of the active.
31. A composition according to claim 28 or 29 which contain N-formyl desloratadine less man 0.6% by weight of the active.

32. A composition according to claim 28 or 29 which contains N-formyl desloratadine less than 0.5% by weight of the active.

33. A composition according to any one of claims 28 to 32 wherein the composition has been stored at about 25°C and about 60% relative humidity.

34. A stable pharmacentical composition according to any one of claims 1 to 33 which is a soild pharmaceutical composition.
35. A stable pharmaceutical composition comprising desloratadine or a pharmaceutically acceptable sail; solvate, derivative, polymorph, hydrates or enantiomer thereof, and a carrier comprising at least one polyol selected from mannitol, maltitol, sorbitol, lactitol, erythritol, or xylitol or a mixture of two or more thereof; wherein the composition does not contain stearic acid and derivatives thereof; and containing N-formyl desloratadine less than 0.75% by weight of the active.
36. The use of a polyol selected from mannitol, maltitol, sorbitol, lactitol, erythritol
xylitol or a mixture of two or more thereof to stabilise a. pharmaceutical composition
comprising desloratadine, •wherein me composition does not contain stearic acid and
derivatives thereof
37. The use according to claim 36 wherein the polyol is mannitol.
38 . A composition according to any one of claims 1 to 35 for use as a medicament.
26

-26-
39. The use of a composition according to any one of claims 1 to 36 for the manufacture of a medicament for treating conditions responsive to administration of an antihistamine..
40. A process for making a stable pharmaceutical composition according to any one of claims 1 to 35 which process comprises blending the ingredients and formulating them so as to form said composition.
41. A process for making a stable pharmaceutical tablet composition according to any one of claims 1 to 35 acceptable excipients, which process comprises blending the ingredients and compressing to form a tablet.
42. A method of treating a condition responsive to administration of an antihistamine, which method comprises administering to a patient in need thereof a composition as claimed in
any one of claims 1 to 35.
43. A stable pharmaceutical composition, use of polyol to stabilize the said
composition, process for making the said composition and method of treatment
substantially as herein described with reference to the foregoing examples.


Dated this 8th day of February, 2007

27

ABSTRACT
‘ANTI-HISTAMINIC COMPOSITION ‘
A stable pharmaceutical composition comprises desloratadine or a pharmaceutically acceptable salt, solvate, derivative, polymorph, hydrate or enantiomer thereof, and a carrier comprising at least one polyol. Preferred compositions comprise, in addition to desloratadine, from 50 to 80% polyol, from 5 to 15% disintegrating agent, and from 0.01 to 0.5% antioxidant and /or a chelating agent, all by weight of composition. There is also provided the use of a polyol to stabilise a pharmaceutical composition comprising desloratidine. A process for making a stable pharmaceutical composition comprising desloratdine and one or more polyols, optionally together with other pharmaceutically acceptable excipients comprises blending the ingredients and formulating.
28